ReviewFrontiers in immunology2026
WWP2 in immune surveillance and antigen presentation: context-dependent roles in B cells, T cells, and tumor immune escape.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
WWP2 is a NEDD4-family HECT E3 ubiquitin ligase with emerging relevance to immune regulation and cancer immunity. Although WWP2 has been widely studied in tumor growth, fibrosis, and cell signaling, its immune functions are less consistently integrated into current models of cancer immune surveillance. This review summarizes the structural and regulatory features of WWP2 and examines how its substrate- and adaptor-dependent activities influence B cell tolerance, helper T cell responses, innate immune signaling, and tumor immune escape. Particular attention is given to the SUSD6/TMEM127/WWP2 axis, which promotes MHC-I ubiquitination and lysosomal degradation, thereby reducing cell-surface antigen presentation and potentially weakening cytotoxic T cell recognition. By separating immune, tumor-intrinsic, and context-specific mechanisms, we highlight WWP2 as a conditional regulator of antigen presentation rather than a uniformly oncogenic ligase. A more precise understanding of WWP2-dependent immune pathways may support biomarker development and guide therapeutic strategies that restore antigen presentation or selectively disrupt pathogenic adaptor-ligase interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.